On January 11, 17 pharmaceutical stocks in the two cities had block trading, and 3 of them had a turnover of more than 300 million yuan

According to the data center of Oriental Wealth Network, on January 11, a total of 88 stocks in the two cities underwent large transactions, with a total transaction volume of 3.
53 billion yuan
.
From the perspective of its industry, according to statistics, there are 17 stocks in the pharmaceutical and biological industry, including Hengrui Pharmaceutical, WuXi AppTec, Kailaiying and so on
.
Specifically, in terms of turnover, Hengrui Pharmaceutical ranked first with a total turnover of 862 million yuan on the 11th, with 22 transactions and a total transaction volume of 23.
4675 million shares
.
WuXi AppTec followed closely behind, with a total trading volume of 597 million yuan on the 11th, 17 transactions, and a total transaction volume of 7.
0605 million shares
.
The turnover of Kailaiying also exceeded 300 million yuan, reaching 371 million yuan, with 36 transactions and a total transaction volume of 2.
6049 million shares
.
In terms of average transaction price, the average transaction price of three stocks of Kaileying, BeiGene and Tigermed Pharma was more than 100 yuan, and the average transaction price of WuXi AppTec, Zhaoyan New Drug, Yifeng Pharmacy and Yunnan Baiyao exceeded 50 yuan
.
In terms of discount rate, 5 stocks including Yunnan Baiyao, Darentang, Tigermed Pharmaceutical, Yifeng Pharmacy and Zhaoyan New Drug all had a discount rate of 0, and the remaining 12 stocks had a negative
discount rate.
In addition, from the perspective of rise and fall, among the 17 pharmaceutical stocks that have been traded in large quantities, as of the close of January 11, a total of 7 stocks rose, including Asiahong Pharmaceutical, BeiGene, Huiyu Pharmaceutical, Addi Pharmaceutical, Kaileying, Tigermed Pharmaceutical, WuXi AppTec, etc.
, of which Asiahong Pharma closed up as much as 12.
24% on the 11th, closing at 12.
20 yuan
.
It is worth mentioning that among the above 17 stocks that have undergone large transactions, many stocks belong to the CRO segment, including WuXi AppTec, Kaileying, Tigermed Pharmaceutical, Zhaoyan New Drug, etc
.
According to the data, block transactions refer to securities transactions
in which the number or transaction amount of a single securities declaration reaches the relevant regulations, and the buyer and seller reach an agreement and are traded through the block trading system of the exchange.
Large trades in stocks generally send buy signals, sell signals and buy signals
.
It is understood that when there are continuous large transactions in stocks, it is necessary to see whether the transaction is at a discount or at a premium, and the frequent large transactions and premium transactions occur in the fund-absorbing stage, which may be to attract the attention of retail investors and help the stock price rise; In a downtrend, large transactions occur frequently and are traded at a discount, possibly because major shareholders sell arbitrage, which is not conducive to the rise
in stock prices.
However, the stock market is ever-changing, and the industry believes that it is necessary to conduct a comprehensive analysis
based on fundamentals combined with technical aspects.
Recently, affected by the opening of negotiations on the medical insurance drug catalog, the CRO concept sector as a whole has shown a trend of shock and rise, on January 11, Nuotai Biotech appeared in the intraday 20CM price limit, Kailaiying, Kanglong Chemical, Medixi, Zhaoyan New Drug and other stocks have also followed
。 From the fundamental perspective of the CRO industry, the innovative drug industry has developed rapidly in recent years, but the cost of new drug research and development continues to rise, the research and development cycle is long, the success rate is low, and the return period is long, CRO enterprises have become an important link in the pharmaceutical R & D industry chain, superimposed on China's engineer dividend, overseas enterprises' orders are rapidly transferred to the mainland and other factors, it is expected that the future CRO industry growth space is still broad
。 According to Frost & Sullivan, global CRO services revenue reached $67.
2 billion in 2020 and is expected to reach $96 billion in 2024, with a CAGR of 9.
3%
from 2020 to 2024.
In China, the scale of the CRO industry was 67.
8 billion yuan in 2018, showing a rapid growth trend
.
The industry estimates that this market could reach $17.
2 billion by 2023.

Disclaimer: Under no circumstances does the information or opinions expressed herein constitute investment advice
to anyone.